60 Degrees Pharmaceuticals, Inc. (SXTP)
| Market Cap | 3.31M |
| Revenue (ttm) | 462,612 |
| Net Income (ttm) | -8.17M |
| Shares Out | 7.36M |
| EPS (ttm) | -6.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 773,229 |
| Open | 0.458 |
| Previous Close | 0.473 |
| Day's Range | 0.411 - 0.474 |
| 52-Week Range | 0.411 - 7.200 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Mar 31, 2025 |
About SXTP
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory virus... [Read more]
Financial Performance
In 2023, SXTP's revenue was $253,573, a decrease of -50.40% compared to the previous year's $511,210. Losses were -$3.77 million, -39.08% less than in 2022.
Financial StatementsNews
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / February 21, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Fathom Holdings Inc. (Nasdaq:FTHM) on the RedChip Smal...
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
WASHINGTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseas...
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
WASHINGTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company today announced that the United States Food...
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma closed a $1.075M registered direct offering, raising $2.118M YTD to fund operations. H.C. Wainwright & Co. acted as placement agent.
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma (SXTP) announces a $1.075M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseas...
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient...
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women's Hospital resear...
VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (Nasdaq:VSEE) and 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) on the RedChip Small Stocks, Bi...
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on ...
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-...
Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying
The Dow Jones index closed higher by more than 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectio...
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ($124 thousand) to $35 thousand, ...
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq's $1.00 minimum bid price requirement.
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K.
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new...
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in h...